Novel inflammatory-nutritional prognostic index for advanced gastric cancer patients undergoing gastrectomy and prophylactic hyperthermic intraperitoneal chemotherapy

Table 4 Univariate and multivariate analyses of baseline characteristics for overall survival in 181 advanced gastric cancer patients

Patients’ characteristics	Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value
Sex (male vs female)	0.78 (0.52-1.15)	0.209	0.94 (0.63-1.41)	0.780
Age at diagnosis, years (> 60 vs ≤ 60)	6.98 (3.92-12.4)	< 0.001	3.66 (1.97-6.80)	< 0.001
INPI groups
Medium risk vs low risk	3.23 (2.08-5.00)	< 0.001	3.70 (2.29-5.98)	< 0.001
High risk vs low risk	15.0 (8.17-27.57)	< 0.001	9.81 (4.97-19.37)	< 0.001
NRS 2002 (> 5 vs ≤ 5)	4.18 (2.40-7.29)	< 0.001	1.88 (1.03-3.40)	0.037
ASA score
2 vs 1	0.76 (0.10-5.56)	0.794
3 vs 1	0.86 (0.11-6.29)	0.888
4 vs 1	1.35 (0.08-21.75)	0.830
pT stage (pT4 vs pT3)	4.46 (2.68-7.42)	< 0.001	2.06 (1.08-3.94)	0.028
pN stage
N2 vs N1	3.70 (2.09-6.53)	< 0.001	3.77 (1.83-7.78)	< 0.001
N3 vs N1	9.83 (5.70-16.96)	< 0.001	6.69 (3.30-13.56)	< 0.001
pTNM stage (IV vs III)	6.93 (3.34-14.40)	< 0.001	1.49 (0.5-4.54)	0.477
Pathological tumor type
Mucinous adenocarcinoma or signet-ring cell carcinoma vs adenocarcinoma	1.07 (0.67-1.72)	0.758
Tumor site
Body/angulus vs cardia/fundus	1.09 (0.26-4.55)	0.901
Antrum/pylorus vs cardia/fundus	0.92 (0.22-3.78)	0.916
Histological grade (G3 vs G1/G2)	12.8 (0.80-2.04)	0.309
Lymphovascular invasion (yes vs no)	3.37 (2.13-5.32)	< 0.001	1.91 (1.17-3.13)	0.010
Surgical procedure (open surgery vs laparoscopic surgery)	1.25 (0.83-1.90)	0.279
Reconstruction method
Billroth II + Braun vs Roux-en-Y	1.068 (0.69-1.64)	0.763
Billroth I vs Roux-en-Y	0.894 (0.21-3.64)	0.876
Heat perfusion frequency
2 times vs 1 time	0.79 (0.40-1.55)	0.498
3 times vs 1 time	0.86 (0.58-2.34)	0.658
Extent of gastric resection (distal vs total)	0.98 (0.65-1.49)	0.946

HR: Hazard ratio; INPI: Inflammatory nutritional prognostic index; NRS 2002: Nutritional Risk Screening 2002; ASA: American Society of Anesthesiologists; TNM: Tumor-node-metastasis.